: Alkermes shares surge after settlement with Teva on alcohol dependence treatment
Shares of Alkermes PLC ALKS jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA relating to Vivitrol, a treatment for alcohol and opioid dependence. The settlement agreement, which will be submitted for regulatory review, gives Teva a license to market a generic version of Vivitrol in the U.S. starting in early 2027, Alkermes said in a release. The settlement “lifts a key overhang” on the stock, and the... Читать дальше...